Outcome of Progressive Multifocal Leukoencephalopathy Treated by Interleukin-7.
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
30
12
2021
received:
12
11
2021
accepted:
02
01
2022
pubmed:
25
1
2022
medline:
6
5
2022
entrez:
24
1
2022
Statut:
ppublish
Résumé
Restoring anti-JC virus (JCV) immunity is the only treatment of progressive multifocal leukoencephalopathy (PML). Interleukin-7 is a cytokine that increases number and function of T cells. We analyzed a population of PML patients who received recombinant human IL-7 (rhIL-7) to estimate survival and its determinants. After exclusion of patients with missing data or receiving other immunotherapies, findings from 64 patients with proven PML who received rhIL-7 between 2007 and 2020 were retrospectively analyzed. Logistic regression was used to analyze variables associated with one-year survival. Underlying conditions were HIV/AIDS (n = 27, 42%), hematological malignancies (n = 16, 25%), primary immunodeficiencies (n = 13, 20%), solid organ transplantation (n = 4, 6%) and chronic inflammatory diseases (n = 4, 6%). One-year survival was 54.7% and did not differ by underlying condition. Survival was not associated with baseline characteristics, but with a >50% increase in blood lymphocytes (OR 4.1, 95%CI 1.2-14.9) and CD4 In this non-controlled retrospective study, survival did not differ from that expected in HIV/AIDS patients, but might have been improved in those with hematological malignancies, primary immunodeficiencies and transplant recipients. RhIL-7 might have contributed to the increase in blood lymphocytes and decrease in CSF JCV replication that were associated with better survival. ANN NEUROL 2022;91:496-505.
Substances chimiques
Interleukin-7
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
496-505Investigateurs
Alexa Debard
(A)
Pierre Delobel
(P)
Nathalie Pansu
(N)
Cédric Gollion
(C)
Marie Benaiteau
(M)
Christine Jacomet
(C)
Nicolas Mélé
(N)
Antoine Moulignier
(A)
Felipe Suarez
(F)
Yvon Ruch
(Y)
Christine Tranchant
(C)
Adrien Lemaignen
(A)
Sophie Langner-Lemercier
(S)
Rodolphe Buzele
(R)
Aurelien Guffroy
(A)
Cécile Moluçon-Chabrot
(C)
Pierre Tattevin
(P)
Giovanna Melica
(G)
Carmen-Ionela Badiu
(CI)
Chrystel Cheraud-Bonfort
(C)
Anne Salmon
(A)
Karl Bjornar Alstadhaug
(KB)
F Matthew Kuhlmann
(FM)
Lucas Gorza
(L)
Adrien Wang
(A)
Heidi Wille
(H)
Elodie Curlier
(E)
Mojgan Hessamfar
(M)
Florent Valour
(F)
Thomas Perpoint
(T)
Igor J Koralnik
(IJ)
Kevin Decaestecker
(K)
William Vindrios
(W)
Anne Guilbert
(A)
Jean Marc Boulesteix
(JM)
Sylvie Colin De Verdière
(SC)
Antoine Roux
(A)
Amila Patel
(A)
Michelle Fabian
(M)
Asaff Harel
(A)
Benjamin Wyplosz
(B)
Florence Ader
(F)
Informations de copyright
© 2022 American Neurological Association.
Références
Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol 2021;17:37-51.
Khanna N, Wolbers M, Mueller NJ, et al. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol 2009 May;83:4404-4411.
Du Pasquier RA, Kuroda MJ, Zheng Y, et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004;127:1970-1978.
Cortese I, Muranski P, Enose-Akahata Y, et al. Pembrolizumab treatment for progressive multifocal Leukoencephalopathy. N Engl J Med 2019;380:1597-1605.
Berzero G, Basso S, Stoppini L, et al. Adoptive transfer of JC virus-specific T lymphocytes for the treatment of progressive multifocal Leukoencephalopathy. Ann Neurol 2021;89:769-779.
Stefoski D, Balabanov R, Waheed R, et al. Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol 2019;6:923-931.
Dubey D, Zhang Y, Graves D, et al. Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature. Ther Adv Neurol Disord 2016;9:211-215.
Oza A, Rettig MP, Powell P, et al. Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient. Blood Adv 2020;4:2387-2391.
Barata JT, Durum SK, Seddon B. Flip the coin: IL-7 and IL-7R in health and disease. Nat Immunol 2019;20:1584-1593.
Alstadhaug KB, Croughs T, Henriksen S, et al. Treatment of progressive multifocal leukoencephalopathy with interleukin 7. JAMA Neurol 2014;71:1030-1035.
Alstadhaug KB, Hanssen Rinaldo C, Osnes L, et al. PML treated by interleukin-7. Clin Infect Pract 2020;2020:100049.
Gasnault J, de Herve MG, Michot JM, et al. Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy. Open forum Infect Dis 2014;1:ofu074.
Guffroy A, Solis M, Gies V, et al. Progressive multifocal leukoencephalopathy and sarcoidosis under interleukin 7: the price of healing. Neurol Neuroimmunol Neuroinflamm 2020;7:e862.
Guille M, Rousset S, Bonneville F, et al. IL-7 immunotherapy for progressive multifocal leukoencephalopathy in a patient with already controlled HIV-1 infection on antiretroviral therapy. AIDS 2019;33:1954-1956.
Harel A, Horng S, Gustafson T, et al. Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia. J Neurovirol 2018;24:652-655.
Miskin DP, Chalkias SG, Dang X, et al. Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia. Neurol Neuroimmunol Neuroinflamm 2016;3:e213.
Patel A, Patel J, Ikwuagwu J. A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. J Antimicrob Chemother 2010;65:2697-2698.
Ray U, Cinque P, Gerevini S, et al. JC polyomavirus mutants escape antibody-mediated neutralization. Sci Transl Med 2015;7:306ra151.
Soleimani-Meigooni DN, Schwetye KE, Angeles MR, et al. JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7. J Neurovirol 2017;23:141-146.
Sospedra M, Schippling S, Yousef S, et al. Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1. Clin Infect Dis 2014;59:1588-1592.
Dekeyser M, de Goer de Herve MG, Hendel-Chavez H, et al. Refractory T-cell Anergy and rapidly fatal progressive multifocal Leukoencephalopathy after prolonged CTLA4 therapy. Open Forum Infect Dis 2017;4:ofx100.
Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious disease section. Neurology 2013;80:1430-1438.
Koralnik IJ, Wüthrich C, Dang X, et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005;57:576-580.
Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011 may 17;76(20):1697-704.25. Iacobaeus E, Burkill S, Bahmanyar S, et al. the national incidence of PML in Sweden, 1988-2013. Neurology 2018;90:e498-e506.
Gasnault J, Costagliola D, Hendel-Chavez H, et al. Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One 2011;6:e20967.
Marzocchetti A, Tompkins T, Clifford DB, et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009;73:1551-1558.
Adrianzen Herrera D, Ayyappan S, Jasra S, et al. Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant - a case series. Leuk Lymphoma 2019;60:395-401.
Zerbe CS, Marciano BE, Katial RK, et al. Progressive multifocal Leukoencephalopathy in primary immune deficiencies: Stat1 gain of function and review of the literature. Clin Infect Dis 2016;62:986-994.
Mateen FJ, Muralidharan R, Carone M, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 2011;70:305-322.
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016;16:626-638.
Pellegrini M, Calzascia T, Toe JG, et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011;144:601-613.
Levy Y, Lacabaratz C, Weiss L, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009;119:997-1007.
Levy Y, Sereti I, Tambussi G, et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012;55:291-300.
Perales MA, Goldberg JD, Yuan J, et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood 2012;120:4882-4891.
Sheikh V, Porter BO, DerSimonian R, et al. Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia. Blood 2016;127:977-988.
Thiebaut R, Jarne A, Routy JP, et al. Repeated cycles of recombinant human interleukin 7 in HIV-infected patients with low CD4 T-cell reconstitution on antiretroviral therapy: results of 2 phase II multicenter studies. Clin Infect Dis 2016;62:1178-1185.
Sereti I, Estes JD, Thompson WL, et al. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog 2014;10:e1003890.
Sportes C, Hakim FT, Memon SA, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008;205:1701-1714.
Martin-Blondel G, Delobel P, Blancher A, et al. Pathogenesis of the immune reconstitution inflammatory syndrome affecting the central nervous system in patients infected with HIV. Brain 2011;134:928-946.
Datta S, Sarvetnick N. Lymphocyte proliferation in immune-mediated diseases. Trends Immunol 2009;30:430-438.